

bioAffinity stock trades higher as it advances its CyPath Lung test for post-treatment lung cancer surveillance.
You can purchase shares of bioAffinity Technologies (NASDAQ:BIAF) through any online brokerage.
Other companies in bioAffinity Technologies’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN).
There is no analysis for bioAffinity Technologies to provide a consensus price target.
The stock price for bioAffinity Technologies (NASDAQ: BIAF) is $2.83 last updated October 23, 2026 at 5:57 PM EDT.
There are no upcoming dividends for bioAffinity Technologies.
bioAffinity Technologies does not have any upcoming earnings scheduled.
There is no upcoming split for bioAffinity Technologies.
bioAffinity Technologies is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
bioAffinity Technologies Inc develops noninvasive diagnostic laboratory tests to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis informed by machine learning, a form of artificial intelligence...